OmpA and ASP14 in vaccine compositions and as diagnostic targets
AssigneeVirginia Commonwealth University
InventorJason A. Carlyon
Life of this patent
Estimating the term…
Abstract
Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.
Claims5
A method of treating a subject from an Anaplasma phagocytophilum infection comprising administering to said subject an immunogenic composition having at least one polypeptide comprising SEQ ID NO:
- 03 or SEQ ID NO:
- 06.
Dependencies are inferred from the claim text.